BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 36422545)

  • 1. Implications of Fragment-Based Drug Discovery in Tuberculosis and HIV.
    Mallakuntla MK; Togre NS; Santos DB; Tiwari S
    Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36422545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-Based Drug Discovery against Mycobacteria: The Success and Challenges.
    Togre NS; Vargas AM; Bhargavi G; Mallakuntla MK; Tiwari S
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.
    Huang B; Kang D; Zhan P; Liu X
    Expert Opin Drug Discov; 2015 Dec; 10(12):1271-81. PubMed ID: 26372893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors.
    Latham CF; La J; Tinetti RN; Chalmers DK; Tachedjian G
    Curr Top Med Chem; 2016; 16(10):1135-53. PubMed ID: 26324045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Fragment-Based Drug Discovery to Versatile Targets.
    Li Q
    Front Mol Biosci; 2020; 7():180. PubMed ID: 32850968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-based drug discovery-the importance of high-quality molecule libraries.
    Bon M; Bilsland A; Bower J; McAulay K
    Mol Oncol; 2022 Nov; 16(21):3761-3777. PubMed ID: 35749608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
    Urban M; Šlachtová V; Brulíková L
    Eur J Med Chem; 2021 Feb; 212():113139. PubMed ID: 33422979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach.
    Madugula SS; Nagamani S; Jamir E; Priyadarsinee L; Sastry GN
    Mol Divers; 2022 Jun; 26(3):1675-1695. PubMed ID: 34468898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Structure-Based Approach for Group Efficiency Estimation in Fragment-Based Drug Design Using Evaluation of Fragment Contributions.
    Shulga DA; Ivanov NN; Palyulin VA
    Molecules; 2022 Mar; 27(6):. PubMed ID: 35335347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.
    Campaniço A; Moreira R; Lopes F
    Eur J Med Chem; 2018 Apr; 150():525-545. PubMed ID: 29549838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
    Bhat ZS; Rather MA; Maqbool M; Ahmad Z
    Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in fragment-based drug discovery platforms.
    Orita M; Warizaya M; Amano Y; Ohno K; Niimi T
    Expert Opin Drug Discov; 2009 Nov; 4(11):1125-44. PubMed ID: 23480433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico fragment-based drug design.
    Konteatis ZD
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.